+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Human Microbiome Market Research Report by Technology, by Product, by Disease, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • ID: 4857894
  • Report
  • June 2020
  • Region: Global
  • 234 pages
  • 360iResearch
until Jul 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
The Global Human Microbiome Market to Grow USD 2,406.59 Million by 2025, at a CAGR of 22.32%


  • DuPont
  • Merck & Co., Inc.
  • Osel, Inc.
  • Seres Therapeutics
  • Synthetic Biologics Inc.
  • Vithera Pharmaceuticals
  • MORE
The Global Human Microbiome Market is expected to grow from USD 718.37 Million in 2019 to USD 2,406.59 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 22.32%.

Market Segmentation & Coverage:

This research report categorizes the Human Microbiome to forecast the revenues and analyze the trends in each of the following sub-markets:

On the basis of Technology, the Human Microbiome Market is examined across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.

On the basis of Therapeutic Area, the Human Microbiome Market is examined across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women's Health.

On the basis of Product, the Human Microbiome Market is examined across Diagnostic Devices, Drugs, Foods, Medical Foods, Prebiotics, and Probiotics.

On the basis of Disease, the Human Microbiome Market is examined across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.

On the basis of Application, the Human Microbiome Market is examined across Diagnostics and Therapeutics.

On the basis of Geography, the Human Microbiome Market is examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region is examined across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region is examined across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region is examined across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Human Microbiome Market including DuPont, E.I. Du Pont De Nemours and Company, Enterome Bioscience, Merck & Co., Inc., Metabiomics Corporation, Microbiome Therapeutics, LLC, Osel, Inc., Second Genome, Inc., Seres Therapeutics, Synlogic Inc., Synthetic Biologics Inc., Vedanta Biosciences, Inc., Vithera Pharmaceuticals, and Yakult Honsha Co., Ltd..

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Human Microbiome Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Human Microbiome Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Microbiome Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Microbiome Market?
4. What is the competitive strategic window for opportunities in the Global Human Microbiome Market?
5. What are the technology trends and regulatory frameworks in the Global Human Microbiome Market?
6. What are the modes and strategic moves considered suitable for entering the Global Human Microbiome Market?
Note: Product cover images may vary from those shown
2 of 3


  • DuPont
  • Merck & Co., Inc.
  • Osel, Inc.
  • Seres Therapeutics
  • Synthetic Biologics Inc.
  • Vithera Pharmaceuticals
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
2.3.1. Competitive Strategic Window

3. Executive Summary
3.1. Market Outlook
3.2. Technology Outlook
3.3. Therapeutic Area Outlook
3.4. Product Outlook
3.5. Disease Outlook
3.6. Application Outlook
3.7. Geography Outlook
3.8. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Human Microbiome Market, By Geography

5. Market Dynamics
5.1. Introduction
5.1.1. Drivers Increased focus on human microbiome therapy Human microbiome for drug development, early disease detection, and diagnosis
5.1.2. Restraints Limited expertise and lack of comprehensive research
5.1.3. Opportunities Increasing collaborations and research investments to create growth opportunities Development of human microbiome therapeutic products
5.1.4. Challenges Causal links between microbiota dysbiosis and disease

6. Market Insights
6.1. Porters Five Forces Analysis
6.1.1. Threat of New Entrants
6.1.2. Threat of Substitutes
6.1.3. Bargaining Power of Customers
6.1.4. Bargaining Power of Suppliers
6.1.5. Industry Rivalry
6.2. Cumulative Impact of COVID-19
6.3. Client Customizations
6.3.1. Regulatory Framework
6.3.2. Patent & Funding
6.3.3. Impact of Human Microbiome Therapeutics on Current Treatment Options

7. Global Human Microbiome Market, By Technology
7.1. Introduction
7.2. 16s rRNA Sequencing
7.3. Cell Culture Technology
7.4. Computational Tools
7.5. High-Throughput Technology
7.6. Metagenomic Sequencing
7.7. Omics Technology

8. Global Human Microbiome Market, By Therapeutic Area
8.1. Introduction
8.2. Gastrointestinal Disorders
8.3. Metabolic Disorders
8.4. Skin Disorders
8.5. Women’s Health

9. Global Human Microbiome Market, By Product
9.1. Introduction
9.2. Diagnostic Devices
9.3. Drugs
9.4. Foods
9.5. Medical Foods
9.6. Prebiotics
9.7. Probiotics

10. Global Human Microbiome Market, By Disease
10.1. Introduction
10.2. Acute Diarrhea
10.3. Autoimmune Disorders
10.4. Cancer
10.5. Diabetes
10.6. Mental Disorders
10.7. Obesity

11. Global Human Microbiome Market, By Application
11.1. Introduction
11.2. Diagnostics
11.3. Therapeutics

12. Americas Human Microbiome Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Human Microbiome Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. South Korea
13.10. Thailand

14. Europe, Middle East & Africa Human Microbiome Market
14.1. Introduction
14.2. France
14.3. Germany
14.4. Italy
14.5. Netherlands
14.6. Qatar
14.7. Russia
14.8. Saudi Arabia
14.9. South Africa
14.10. Spain
14.11. United Arab Emirates
14.12. United Kingdom

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis
15.3. Market Share Analysis
15.4. Competitive Scenario
15.4.1. Merger & Acquisition
15.4.2. Agreement, Collaboration & Partnership
15.4.3. New Product Launch & Enhancement
15.4.4. Investment & Funding

16. Company Usability Profiles
16.1. DuPont
16.2. E.I. Du Pont De Nemours and Company
16.3. Enterome Bioscience
16.4. Merck & Co., Inc.
16.5. Metabiomics Corporation
16.6. Microbiome Therapeutics, LLC
16.7. Osel, Inc.
16.8. Second Genome, Inc.
16.9. Seres Therapeutics
16.10. Synlogic Inc.
16.11. Synthetic Biologics Inc.
16.12. Vedanta Biosciences, Inc.
16.13. Vithera Pharmaceuticals
16.14. Yakult Honsha Co., Ltd.

17. Appendix
17.1. Discussion Guide
17.2. Edition Details
17.3. License Details
17.4. Pricing Details
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • DuPont
  • E.I. Du Pont De Nemours and Company
  • Enterome Bioscience
  • Merck & Co., Inc.
  • Metabiomics Corporation
  • Microbiome Therapeutics, LLC
  • Osel, Inc.
  • Second Genome, Inc.
  • Seres Therapeutics
  • Synlogic Inc.
  • Synthetic Biologics Inc.
  • Vedanta Biosciences, Inc.
  • Vithera Pharmaceuticals
  • Yakult Honsha Co., Ltd.
Note: Product cover images may vary from those shown